Philippe Armand
Impact in
- Hematology top 0.05%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Pathology and Forensic Medicine top 0.05%
- Lymphoma Diagnosis and Treatment
Papers in
- Oncology 159
- CAR-T cell therapy research 74
- Cancer Immunotherapy and Biomarkers 68
-
- Lymphoma Diagnosis and Treatment 143
- Co-authors
- Joseph H. Antin (118 shared papers)Margaret A. Shipp (50 shared papers)Robert J. Soiffer (113 shared papers)Edwin P. Alyea (107 shared papers)Haesook T. Kim (88 shared papers)Corey Cutler (108 shared papers)Vincent T. Ho (107 shared papers)John Koreth (105 shared papers)
- Journals
- Blood (125 papers)Biology of Blood and Marrow Transplantation (59 papers)Journal of Clinical Oncology (29 papers)Blood Advances (13 papers)Hematological Oncology (12 papers)
- Partner nations
- United StatesCanadaItaly
In The Last Decade
Philippe Armand
325 papers receiving 17.6k citations
Philippe Armand's Hit Papers
Peers
Comparison fields: 5 of 135
- Hematology 4.7k
- Pathology and Forensic Medicine 5.5k
- Oncology 7.9k
- Immunology 5.8k
- Genetics 2.6k
Countries citing papers authored by Philippe Armand
This map shows the geographic impact of Philippe Armand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Armand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Armand more than expected).
Fields of papers citing papers by Philippe Armand
This network shows the impact of papers produced by Philippe Armand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Armand. The network helps show where Philippe Armand may publish in the future.
Co-authors
The 25 scholars most cited alongside Philippe Armand, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 340 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma Hit paper breakdown → | 2014 | 2687 |
| 2 | Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease Hit paper breakdown → | 2011 | 818 |
| 3 | Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma Hit paper breakdown → | 2017 | 702 |
| 4 | Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation Hit paper breakdown → | 2014 | 624 |
| 5 | PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome Hit paper breakdown → | 2016 | 563 |
| 6 | Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure Hit paper breakdown → | 2016 | 481 |
| 7 | Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial Hit paper breakdown → | 2018 | 462 |
| 8 | 1998 | 421 | |
| 9 | 2013 | 373 | |
| 10 | PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma Hit paper breakdown → | 2017 | 342 |
| 11 | 2007 | 318 | |
| 12 | Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy Hit paper breakdown → | 2016 | 316 |
| 13 | 2014 | 287 | |
| 14 | 2014 | 279 | |
| 15 | 2012 | 269 | |
| 16 | 1998 | 268 | |
| 17 | Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study Hit paper breakdown → | 2019 | 253 |
| 18 | 2016 | 231 | |
| 19 | 2019 | 229 | |
| 20 | 2017 | 219 |
About Philippe Armand
Philippe Armand is a scholar working on Oncology, Pathology and Forensic Medicine, Hematology, Immunology and Genetics, having authored 340 papers that have together received 17.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (143 papers), Hematopoietic Stem Cell Transplantation (91 papers), CAR-T cell therapy research (74 papers), Cancer Immunotherapy and Biomarkers (68 papers), Chronic Lymphocytic Leukemia Research (50 papers), Immune Cell Function and Interaction (44 papers), Acute Myeloid Leukemia Research (34 papers) and Acute Lymphoblastic Leukemia research (27 papers). The work is most often cited by research in Hematology (4.7k citations), Pathology and Forensic Medicine (5.5k citations), Oncology (7.9k citations), Immunology (5.8k citations) and Genetics (2.6k citations). Philippe Armand has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Joseph H. Antin, Margaret A. Shipp, Robert J. Soiffer, Edwin P. Alyea, Haesook T. Kim, Corey Cutler, Vincent T. Ho, John Koreth, Scott J. Rodig and Stephen M. Ansell. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Journal of Clinical Oncology, Blood Advances and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.